杭氧股份(002430.SZ)擬為子公司4.9億元借款提供擔保
格隆匯12月8日丨杭氧股份(002430.SZ)發佈公告,2019年12月6日,公司董事會會議審議通過了《關於為全資子公司提供擔保的議案》,同意公司為全資子公司——江西杭氧氣體有限公司(以下簡稱“江西杭氧”)提供擔保,擔保額度為4.9億元人民幣,擔保期限至借款合同項下借款期限屆滿之日起兩年。該擔保額佔公司最近一期經審計歸屬於上市公司股東的淨資產53.0786億元的9.23%,以上擔保額度獲批後,公司及控股子公司累計已批准的對外擔保額度,佔公司最近一期經審計歸屬於上市公司股東的淨資產53.0786億元的35.65%,未超過50%。根據有關規定,上述擔保的議案無需提交公司股東大會審議批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.